SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Organovo (ONVO) announced that it had appointed Norman Staskey as Chief Financial Officer. Don't Miss Our New Year's Offers:Discover the ...

Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary ...

Organovo Holdings, Inc. appointed Norman Staskey as the new President, Chief Financial Officer, and Principal Financial Officer following the resignation of Tomas Hess, who left to pursue retirement.

Stay updated on recent management changes in various companies, including Meta Platforms, Southwest Airlines, and Ulta Beauty.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply ...

Norm has also worked on several recent M&A deals in the biotech industry. “We are excited to welcome Norm to the Organovo team,” said Keith Murphy, Executive Chairman. “With his extensive experience, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...